BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 26712820)

  • 1. Transport-Metabolism Interplay of Atazanavir in Rat Hepatocytes.
    Nicolaï J; De Bruyn T; Thevelin L; Augustijns P; Annaert P
    Drug Metab Dispos; 2016 Mar; 44(3):389-97. PubMed ID: 26712820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic Clearance Prediction of Nine Human Immunodeficiency Virus Protease Inhibitors in Rat.
    De Bruyn T; Augustijns PF; Annaert PP
    J Pharm Sci; 2016 Feb; 105(2):846-853. PubMed ID: 26202434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verapamil hepatic clearance in four preclinical rat models: towards activity-based scaling.
    Nicolaï J; De Bruyn T; Van Veldhoven PP; Keemink J; Augustijns P; Annaert P
    Biopharm Drug Dispos; 2015 Oct; 36(7):462-80. PubMed ID: 25963583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clearance Prediction of HIV Protease Inhibitors in Man: Role of Hepatic Uptake.
    De Bruyn T; Stieger B; Augustijns PF; Annaert PP
    J Pharm Sci; 2016 Feb; 105(2):854-863. PubMed ID: 26213315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosuvastatin Liver Partitioning in Cynomolgus Monkeys: Measurement In Vivo and Prediction Using In Vitro Monkey Hepatocyte Uptake.
    Morse BL; Cai H; MacGuire JG; Fox M; Zhang L; Zhang Y; Gu X; Shen H; Dierks EA; Su H; Luk CE; Marathe P; Shu YZ; Humphreys WG; Lai Y
    Drug Metab Dispos; 2015 Nov; 43(11):1788-94. PubMed ID: 26341276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clearance and clearance inhibition of the HIV-1 protease inhibitors ritonavir and saquinavir in sandwich-cultured rat hepatocytes and rat microsomes.
    Treijtel N; van Eijkeren JC; Nijmeijer S; de Greef-van der Sandt IC; Freidig AP
    Toxicol In Vitro; 2009 Feb; 23(1):185-93. PubMed ID: 19038324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unbound ritonavir concentrations in rat and human hepatocytes.
    Keemink J; Augustijns P; Annaert P
    J Pharm Sci; 2015 Jul; 104(7):2378-87. PubMed ID: 25989229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir.
    Parker AJ; Houston JB
    Drug Metab Dispos; 2008 Jul; 36(7):1375-84. PubMed ID: 18426953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herb-drug interaction between an anti-HIV Chinese herbal SH formula and atazanavir in vitro and in vivo.
    Cheng BH; Zhou X; Wang Y; Chan JY; Lin HQ; Or PM; Wan DC; Leung PC; Fung KP; Wang YF; Lau CB
    J Ethnopharmacol; 2015 Mar; 162():369-76. PubMed ID: 25614104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes.
    Lam JL; Benet LZ
    Drug Metab Dispos; 2004 Nov; 32(11):1311-6. PubMed ID: 15483198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Species-specific interaction of HIV protease inhibitors with accumulation of cholyl-glycylamido-fluorescein (CGamF) in sandwich-cultured hepatocytes.
    Ye ZW; Van Pelt J; Camus S; Snoeys J; Augustijns P; Annaert P
    J Pharm Sci; 2010 Jun; 99(6):2886-98. PubMed ID: 20014428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coupling of an Acyl Migration Prodrug Strategy with Bio-activation To Improve Oral Delivery of the HIV-1 Protease Inhibitor Atazanavir.
    Subbaiah MAM; Meanwell NA; Kadow JF; Subramani L; Annadurai M; Ramar T; Desai SD; Sinha S; Subramanian M; Mandlekar S; Sridhar S; Padmanabhan S; Bhutani P; Arla R; Jenkins SM; Krystal MR; Wang C; Sarabu R
    J Med Chem; 2018 May; 61(9):4176-4188. PubMed ID: 29693401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors.
    Ye ZW; Augustijns P; Annaert P
    Drug Metab Dispos; 2008 Jul; 36(7):1315-21. PubMed ID: 18420783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atazanavir-loaded Eudragit RL 100 nanoparticles to improve oral bioavailability: optimization and in vitro/in vivo appraisal.
    Singh G; Pai RS
    Drug Deliv; 2016; 23(2):532-9. PubMed ID: 24963752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative prediction of the extent of drug-drug interaction using a physiologically based pharmacokinetic model that includes inhibition of drug metabolism determined in cryopreserved hepatocytes.
    Iwasaki S; Hirabayashi H; Amano N
    Xenobiotica; 2018 Aug; 48(8):770-780. PubMed ID: 28851254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay.
    Brown HS; Wilby AJ; Alder J; Houston JB
    Drug Metab Dispos; 2010 Dec; 38(12):2139-46. PubMed ID: 20847136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients.
    Gervasoni C; Riva A; Rizzardini G; Clementi E; Galli M; Cattaneo D
    Antivir Ther; 2015; 20(4):449-51. PubMed ID: 25279606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes.
    Zhou H; Gurley EC; Jarujaron S; Ding H; Fang Y; Xu Z; Pandak WM; Hylemon PB
    Am J Physiol Gastrointest Liver Physiol; 2006 Dec; 291(6):G1071-80. PubMed ID: 16861219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Losartan-Active Carboxylic Acid Metabolite Exposure Following Losartan Administration Using Static and Physiologically Based Pharmacokinetic Models.
    Nguyen HQ; Lin J; Kimoto E; Callegari E; Tse S; Obach RS
    J Pharm Sci; 2017 Sep; 106(9):2758-2770. PubMed ID: 28412400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (Carbonyl)oxyalkyl linker-based amino acid prodrugs of the HIV-1 protease inhibitor atazanavir that enhance oral bioavailability and plasma trough concentration.
    Subbaiah MAM; Ramar T; Subramani L; Desai SD; Sinha S; Mandlekar S; Jenkins SM; Krystal MR; Subramanian M; Sridhar S; Padmanabhan S; Bhutani P; Arla R; Kadow JF; Meanwell NA
    Eur J Med Chem; 2020 Dec; 207():112749. PubMed ID: 33065417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.